ClinicalTrials.gg
CompletedNCT00799656SERENEATIUpdated Apr 1, 2011

Efficacy and Safety Study of Ataciguat Versus Placebo in Patients With Neuropathic Pain

A Phase 2 interventional study of ataciguat (HMR1766) and placebo in Pain, sponsored by Sanofi. Completed at 3 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-04-01.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 51 studies in Pain with a site in Austria — 3 open to participants now, 4 under way, none of them phase 3. Pain · Austria.

Enrollment
28th of 42
62 · median 132
Started
2008
with 2 others
Phase 2
3 of 51
none open now
Registered
10th of 51
by date

Among the 51 studies in Pain with a site in Austria, this one is the 28th largest by enrollment of the 42 interventional ones that give a count, is one of 3 that started in 2008, is one of 3 in phase 2, and was the 10th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,651 are open to participants now.

Browse Pain studies →

Open to participants now

3 of the 51 studies in Pain with a site in Austria are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →

Who these studies take

Of the 928 Pain studies recruiting now, 383 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 222 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Pain with a site in Austria, or all of them as a file.
02

Study summary

The primary objective of this study is to assess the efficacy of ataciguat versus placebo in reducing pain intensity in patients with neuropathic pain.

The secondary objective is to assess the safety and tolerability of ataciguat versus placebo.

Read the detailed description

This study consists of two consecutive 28 day treatment periods which are separated by a 2 week medication free period and a safety follow-up period of 2 weeks after the second treatment period.

03

Conditions studied

  • Pain

Keywords

  • Diabetic neuropathy
  • painful pain
  • postoperative
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with chronic neuropathic pain due to diabetic polyneuropathy or a nerve lesion following surgery. The pain must be present for more than 3 months.

Exclusion criteria

Exclusion Criteria:

  • Presence or history of cancer within the past five years
  • Patients with a history of infection
  • Patients with active or C
  • Patients with any pain other than the neuropathic pain of greater or equal severity
  • Patients with a diabetes mellitus for less than 6 months

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    1

    First period: Ataciguat - Second period: Placebo

    Drug: ataciguat (HMR1766) · Drug: placebo

  • Experimental
    2

    First period: Placebo - Second period: Ataciguat

    Drug: ataciguat (HMR1766) · Drug: placebo

Interventions

  • oral administration 200mg once daily for 28 days

  • Drugplacebo

    oral administration once daily for 28 days

06

What researchers measure

Primary outcomes

  1. Change in average daily pain intensity

    Time frame: after 28-days treatment

Secondary outcomes

  1. Responder rate

    Time frame: after 28-days treatment

  2. Rescue medication intake

    Time frame: during 28-days treatment

  3. Change in Neuropathic Pain Symptom Inventory (NPSI)

    Time frame: after 28-days treatment

07

Study locations

3 sites
  • Sanofi-Aventis Administrative Office
    Wien, Austria
  • Sanofi-Aventis Administrative Office
    Praha, Czech Republic
  • Sanofi-Aventis Administrative Office
    Bucuresti, Romania
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2008, a primary completion of Jun 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2008
First posted
Dec 1, 2008
Start
Nov 2008
Primary completionActual
Jun 2009
CompletionActual
Sep 2009
Last update
Apr 1, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00799656
Lead sponsor
Sanofi
First posted
Dec 1, 2008
Start date
Nov 2008
Primary completion
Jun 2009
Completion
Sep 2009
Last update
Apr 1, 2011

Study contacts

Hans-Goerg Kress, Professor
principal investigator · Medizinische Universität / AKH Wien - Währinger Gürtel 18-20 - A-1090 Wien

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ataciguat

Start the discussion